Bio-Connect

NFKB2 Antibody, Biotin conjugated

Research Use Only
CSB-PA10449D0RB
Cusabio
ApplicationsELISA
Product group Antibodies
ReactivityHuman
TargetNFKB2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Cusabio
  • Product Name
    NFKB2 Antibody, Biotin conjugated
  • Delivery Days Customer
    20
  • Applications
    ELISA
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Conjugate
    Biotin
  • Gene ID4791
  • Target name
    NFKB2
  • Target description
    nuclear factor kappa B subunit 2
  • Target synonyms
    CVID10; DNA-binding factor KBF2; H2TF1; lymphocyte translocation chromosome 10 protein; LYT10; LYT-10; NFKB, p52/p100 subunit; NF-kB2; nuclear factor Kappa-B, subunit 2; nuclear factor NF-kappa-B p100 subunit; nuclear factor NF-kappa-B p52 subunit; nuclear factor of Kappa light chain gene enhancer in B cells 2; nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100); oncogene Lyt-10; p100; p49/p100; p52; transcription factor NFKB2
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ00653
  • Protein Name
    Nuclear factor NF-kappa-B p100 subunit
  • Scientific Description
    NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5\-GGRNNYYCC-3\, located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C
  • UNSPSC
    12352203